These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. Pitot HC; Wender DB; O'Connell MJ; Schroeder G; Goldberg RM; Rubin J; Mailliard JA; Knost JA; Ghosh C; Kirschling RJ; Levitt R; Windschitl HE J Clin Oncol; 1997 Aug; 15(8):2910-9. PubMed ID: 9256135 [TBL] [Abstract][Full Text] [Related]
23. Rationale for the dosage and schedule of CPT-11 (irinotecan) selected for phase II studies, as determined by European phase I studies. Armand JP; Extra YM; Catimel G; Abigerges D; Marty M; Clavel M Ann Oncol; 1996 Oct; 7(8):837-42. PubMed ID: 8922198 [TBL] [Abstract][Full Text] [Related]
24. Irinotecan hydrochloride for the treatment of recurrent and refractory non-Hodgkin lymphoma: a single institution experience. Sugiyama K; Omachi K; Fujiwara K; Saotome T; Mizunuma N; Takahashi S; Ito Y; Aiba K; Horikoshi N Cancer; 2002 Feb; 94(3):594-600. PubMed ID: 11857289 [TBL] [Abstract][Full Text] [Related]
25. [A late phase II clinical study of RP56976 (docetaxel) in patients with advanced or recurrent gastric cancer: a cooperative study group trial (group B)]. Mai M; Sakata Y; Kanamaru R; Kurihara M; Suminaga M; Ota J; Hirabayashi N; Taguchi T; Furue H Gan To Kagaku Ryoho; 1999 Mar; 26(4):487-96. PubMed ID: 10097745 [TBL] [Abstract][Full Text] [Related]
26. Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer. Yi SY; Park YS; Kim HS; Jun HJ; Kim KH; Chang MH; Park MJ; Uhm JE; Lee J; Park SH; Park JO; Lee JK; Lee KT; Lim HY; Kang WK Cancer Chemother Pharmacol; 2009 May; 63(6):1141-5. PubMed ID: 18839175 [TBL] [Abstract][Full Text] [Related]
27. [Phase I clinical study of CPT-11. Research group of CPT-11]. Taguchi T; Wakui A; Hasegawa K; Niitani H; Furue H; Ohta K; Hattori T Gan To Kagaku Ryoho; 1990 Jan; 17(1):115-20. PubMed ID: 2404454 [TBL] [Abstract][Full Text] [Related]
28. Phase I study of weekly intravenous infusions of CPT-11, a new derivative of camptothecin, in the treatment of advanced non-small-cell lung cancer. Negoro S; Fukuoka M; Masuda N; Takada M; Kusunoki Y; Matsui K; Takifuji N; Kudoh S; Niitani H; Taguchi T J Natl Cancer Inst; 1991 Aug; 83(16):1164-8. PubMed ID: 1653362 [TBL] [Abstract][Full Text] [Related]
29. A phase I and pharmacokinetic study of pegylated camptothecin as a 1-hour infusion every 3 weeks in patients with advanced solid malignancies. Rowinsky EK; Rizzo J; Ochoa L; Takimoto CH; Forouzesh B; Schwartz G; Hammond LA; Patnaik A; Kwiatek J; Goetz A; Denis L; McGuire J; Tolcher AW J Clin Oncol; 2003 Jan; 21(1):148-57. PubMed ID: 12506184 [TBL] [Abstract][Full Text] [Related]
30. CPT-11 in the treatment of colorectal cancer: clinical efficacy and safety profile. Rougier P; Bugat R Semin Oncol; 1996 Feb; 23(1 Suppl 3):34-41. PubMed ID: 8633252 [TBL] [Abstract][Full Text] [Related]
31. Salvage chemotherapy with CPT-11 for recurrent meningioma. Chamberlain MC; Tsao-Wei DD; Groshen S J Neurooncol; 2006 Jul; 78(3):271-6. PubMed ID: 16628476 [TBL] [Abstract][Full Text] [Related]
32. Phase II study of irinotecan in prior chemotherapy-treated squamous cell carcinoma of the cervix. Verschraegen CF; Levy T; Kudelka AP; Llerena E; Ende K; Freedman RS; Edwards CL; Hord M; Steger M; Kaplan AL; Kieback D; Fishman A; Kavanagh JJ J Clin Oncol; 1997 Feb; 15(2):625-31. PubMed ID: 9053486 [TBL] [Abstract][Full Text] [Related]
33. [Weekly chemotherapy with alternating low-dose CPT-11 and low-dose FP against a far advanced pancreatic cancer--a case report]. Takahashi Y; Kitagata S; Mai M Gan To Kagaku Ryoho; 2000 Sep; 27(10):1581-4. PubMed ID: 11016006 [TBL] [Abstract][Full Text] [Related]
35. [Four cases of recurrent breast cancer effectively treated by the new antitumor agent, CPT-11 (irinotecan)]. Doihara H; Takashima S; Yokoyama N Gan To Kagaku Ryoho; 1994 Jul; 21(8):1263-6. PubMed ID: 8031169 [TBL] [Abstract][Full Text] [Related]
36. CPT-11. The European experience. Armand JP; Terret C; Couteau C; Rixe O Ann N Y Acad Sci; 1996 Dec; 803():282-91. PubMed ID: 8993522 [TBL] [Abstract][Full Text] [Related]
37. A phase II trial of CPT-11 in recurrent squamous carcinoma of the cervix: a gynecologic oncology group study. Look KY; Blessing JA; Levenback C; Kohler M; Chafe W; Roman LD Gynecol Oncol; 1998 Sep; 70(3):334-8. PubMed ID: 9790784 [TBL] [Abstract][Full Text] [Related]
38. [Preventive effect of TJ-14, a kampo (Chinese herb) medicine, on diarrhea induced by irinotecan hydrochloride (CPT-11)]. Sakata Y; Suzuki H; Kamataki T Gan To Kagaku Ryoho; 1994 Jul; 21(8):1241-4. PubMed ID: 8031168 [TBL] [Abstract][Full Text] [Related]
39. A phase II study of pegylated-camptothecin (pegamotecan) in the treatment of locally advanced and metastatic gastric and gastro-oesophageal junction adenocarcinoma. Scott LC; Yao JC; Benson AB; Thomas AL; Falk S; Mena RR; Picus J; Wright J; Mulcahy MF; Ajani JA; Evans TR Cancer Chemother Pharmacol; 2009 Jan; 63(2):363-70. PubMed ID: 18398613 [TBL] [Abstract][Full Text] [Related]
40. [An early phase II clinical study of RP56976 (docetaxel) in patients with cancer of the gastrointestinal tract]. Taguchi T Gan To Kagaku Ryoho; 1994 Oct; 21(14):2431-7. PubMed ID: 7944488 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]